Aquamarine Financial (Cayman) Ltd Increases Stake in Oramed Pharmaceuticals Inc. to 5.06%

Aquamarine Financial (Cayman) Ltd filed a Schedule 13G on May 15, 2026, reporting a 5.06% stake in Oramed Pharmaceuticals Inc. (ORMP). As of the event date on January 14, 2026, the filer beneficially owns 2,047,652 shares of Common Stock. This represents an increase from their previously reported position of 1,973,057 shares. The filing indicates that Aquamarine Financial (Cayman) Ltd has sole voting and dispositive power over the entire reported amount. The securities were acquired in the ordinary course of business and not for the purpose of influencing or changing the control of the issuer. The reporting person is based in the Cayman Islands and filed under Rule 13d-1(c). The total value of the holdings is estimated at approximately $9.5 million based on recent market data.